Cost and Resource Studies in Endometriosis: An Evidence Map

Author(s)

Ahdesmaki O1, Springate C2, Martin A2
1Crystallise Ltd, Stanford-le-Hope, UK, 2Crystallise Ltd., Essex, ESS, UK

Presentation Documents

OBJECTIVES: According to current estimates, at least 190 million patients worldwide are affected by endometriosis during their reproductive age. Endometriosis has bearing on society through direct and indirect costs comparable to most common diseases (e.g. diabetes). We created an evidence map of cost and resource use (CRU) studies in patients with endometriosis.

METHODS: We searched www.heoro.com/ database for CRU studies in endometriosis and indexed them into an online Evidence Map according to study type, types of outcomes reported, comorbidities, and symptoms cited across the geographical locations.

RESULTS: A total of 84 abstracts were identified and after screening by a researcher, 73 were found to be relevant. The publications reported data from 26 different geographical locations, the majority originating from the US (32 publications). 16 publications reported data internationally, three of which were systematic reviews. Among the remaining 70 publications, 39 were observational, 12 were narrative reviews, 10 were economic models, and nine were RCTs. Costs related to healthcare (46) were most commonly reported, followed by resource use (23) and hospitalisation data (22). Indirect cost outcomes included productivity and working hour losses (17 publications), career choices and progression, employment status, sick leave and return to work. 14 publications reported operative time while 10 reported on length of stay.

CONCLUSIONS: The majority of data originated from the US, with studies focusing on healthcare costs and resource use. In contrast, studies from Europe were as likely to report on productivity losses and impact on employment as on healthcare-related costs. Studies from China and India also focused on direct costs, while direct and indirect costs were reported by Brazilian publications. The was a distinct lack of RCT data despite recent recommendations to conduct more sufficiently powered randomised clinical trials in different countries and cultural backgrounds to directly assess the costs of different treatments.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

EE261

Topic

Economic Evaluation

Topic Subcategory

Work & Home Productivity - Indirect Costs

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×